Docetaxel: its role in current and future treatments for advanced gastric cancer.

摘要: A globally accepted standard chemotherapy remains undetermined in gastric cancer, but the recent introduction of active “new-generation agents” such as taxanes, irinotecan (CPT-11), oxaliplatin, S-1, and capecitabine, offers hope for markedly improving patient outcomes. Docetaxel, well other new-generation agents, plays a key role development new-era chemotherapy, incorporation taxanes has provided several regimens, docetaxel/cisplatin/5-fluorouracil (5-FU) (DCF), that could become treatment. The DCF regimen is now regarded treatment option advanced cancer selected patients good condition. Many institutions cooperative groups continue to study variety docetaxel-based combinations with cytotoxic various settings, attention been focused on biological cetuximab, bevacizumab, everolimus, sunitinib, into docetaxel-containing another innovative approach. ongoing clinical trials number new regimens will clarify their benefits Along more docetaxel combination identification predictive biomarkers each intensively studied recently. This review focuses agent discusses this taxane current future treatments cancer.